Defense Therapeutics Inc. got dr. Svetlana Selivanova, expert for radiopharmaceutika, on the board of directors

Vancouver, BC, Canada, November 13, 2024 / IRW-Press / Defense Therapeutics Inc. (“Defence” oder das “Unternehmen”) (CSE: DTC, OTCQB: DTCFF, FWB: DTC), a Canadian biopharmaceutical group that does not work New immunological agents, radiopharmaceuticals and new plastics ADC products that have a proprietary platform and creative technology possess, can contribute to Dr. Svetlana Selivanova from the Board of Directors with such a better Wirkung beigetreten ist.

Dr. Svetlana Selivanova is a radiochemist with more than 20 years of research in the development of radiopharmaceuticals – from the early research and research to its most clinical research in humans. You have obtained an MSc-Abschluss in Chemistry and a PhD-Abschluss in radiopharmaceutical Chemistry and Radiobiology. He is the department head for Radiochemistry and Medical Applications (in etwa: Abteilungsleiterin für Radiochemistry and Medizinische Anwendungen) at Canadian Nuclear Laboratories (CNL) and Lehrbeauftragte en der Fakultät for Pharmazie der Université Laval. For your Tätigkeit at CNL, you have a leading position in Research and Management at the CHU of Quebec-Université Laval, at the Sherbrooke University Hospital and at the Center for Radiopharmaceutical Science of the ETH Zurich (Schweiz).

Dr. Selivanova is active in business and serves, among other things, as an executive member of the Canadian Association of Radiopharmaceutical Scientists, as chairman of the SNMMI Radiopharmaceutical Sciences Council and as chairman of the SNMMI Committee on Radiopharmaceuticals. International atomic energy companies and the European Research Council are active internationally. Dr. Selivanovas has shown interest in the development and development of new radiopharmaceuticals in work in clinical application and in nuclear energy as an instrument for a biochemical development in vivo. These are the main research and development activities for the production of Technetium-99m with a zyklotron and the development of a radiopharmaceutical for prostate cancer, which acts on the prostate gland membranes.

“We are happy to inform you that Dr. Svetlana Selivanova is a member of the Board of Directors. You will be able to use your own information in a comprehensive manner. The Strategy of Defense is based on the development of radioimmune technology under the use of an accumulator platform. Dr. Selivanova is based on a comprehensive approach ntnisse and success in the development and development of our radiopharmaceutical programs,” said Sébastien Plouffe, President, CEO and Gründer von Defense Therapeutics.

“It is a Ehre, as part of the Defense Therapeutics Board of Directors. Defense’s Accum Technology Platform is one of the greatest opportunities for the Entwicklung, soul-oriented radiopharmaceutical therapy on,” said Dr. Svetlana Selivanova.

Das Unternehmen hat Dr. Svetlana Selivanova 100.000 Incentive-Aktienoptionen in Übereinstimmung met de Bedingungen des Aktienoptionsplans von Defense gewährt. The promotion option can be removed so easily and can once last a year before the purchase date gets a price of 60 cents for the promotion being performed.

The Unternehmen can take charge of Dr. Raimar Lobenberg from the Board of Directors in zurücktritt. Our colleagues would like to thank Dr. Lobenberg for his work on the Board of Directors.

Uber Defense:

Defense Therapeutics is one of the best, in the clinical stage of the biotech industry, there are new immunological impfants for a more robust proprietary platform of the next generation of radioimmune diseases and ADC products. The core of the Defense Therapeutics platform is the best in ACCUM technology, the transport of radioimmune compounds or ADCs in the intakter form of the Zielzellen is light, so impfantigens. If you take the next step, you can experience improved functioning and functioning that will improve the functioning of credits and infectious diseases.

More information and further information:

Sebastien Plouffe, President, CEO and Director

Phone: (514) 947-2272

email to:[email protected]

http://www.defensetherapeutics.com

Vorsorglicher Hinweis bezüglich “zukunftsgerichteter” Informationen

The CSE and the market regulatory body (which is the Begriff towards the CSE definition) do not have any responsibility for the Angemessenheit or Richtigkeit dieser Mitteilung.

The Ausgangssprache (in the Rule English), in the original text which is light, is the official, authorizing and legally binding version. These instructions can be carried out with confidence. The German language can be kürzt or jijammengefasst. There is no Verantwortung or Haftung für de Inhalt, de Direction, de Angemessenheit or de Genauigkeit dieser Übersetzung übernommen. Aus Sicht des Übersetzers stelltt die Notification keine Kauf- oder Verkaufsempfehlung dar! Bitte beachten See the English original report on www.sedarplus.ca, www.sec.gov, www.asx.com.au/ or on the Firmen website!

The English original notification can be found under the following link:
https://www.irw-press.at/press_html.aspx?messageID=77446
The übersetzte Notification finds the following link:
https://www.irw-press.at/press_html.aspx?messageID=77446&tr=1

SUBSCRIBE TO NEWSLETTER:

Aktuelle Pressemeldungen die Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=de&isin=CA24463V1013

Mitteilung übermittelt by IRW-Press.com. The justifiable effect is for inhalation.

Kostenloser Abdruck mit Quellenangabe erlaubt.

https://www.wallstreet-online.de/nachricht/18706273-defence-begruesst-dr-svetlana-selivanova-expertin-radiopharmazeutika-board-of-directors